As India’s contract manufacturing and development organization (CDMO) is set to double in the next decade, Anthem Biosciences is planning to raise 33.95 billion rupees ($397m) in an initial public ...

Anthem Biosciences, an India-based CDMO, submitted a filing (PDF) at the end of 2024 to announce its plans for a 33.95 ...

(Reuters) -Indian contract drugmaker Anthem Biosciences filed for a 33.95-billion ... are among investors who will sell shares in the IPO. The company will not sell any shares and it did not ...

Contract research company Anthem Biosciences has filed for a Rs 3,395 ... The selling shareholders will be entitled to the proceeds from the IPO and the company will not receive any proceeds ...

Indian contract drugmaker Anthem Biosciences filed for a 33.95-billion-rupee ($397 ... North and drugmaker DavosPharma are among investors who will sell shares in the IPO. The company will not sell ...

Dec 31 (Reuters) - Indian contract drugmaker Anthem Biosciences filed for a 33.95-billion ... are among investors who will sell shares in the IPO. The company will not sell any shares and it ...

Anthem Biosciences Limited, an innovation-driven and technology ... SEBI to raise funds through an initial public offering (IPO). Ajay Bhardwajm, chairman, MD & CEO, Ishaan Bhardwaj, vice president, ...

Since the IPO is entirely an OFS, the company will not receive any ... Suven Life Sciences and Divi's Laboratories are the listed peers of Anthem Biosciences, as per the DRHP. JM Financial Ltd, ...

Indian drugmaker Anthem Biosciences filed for a 33.95-billion-rupee ($397 million) initial public offering, draft papers showed on Tuesday. Anthem will not issue new shares in the IPO. ($1 = 85.5720 I ...